SEC Company Response from AGENUS INC (AGEN) (CIK 0001098972) (AGEN) — Nov 8, 2019
AGENUS INC (AGEN) (CIK 0001098972)
Date: Nov. 8, 2019 · CIK: 0001098972 · Accession: 0001193125-19-288314
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-29089
Referenced dates: October 7, 2019
Letter
ROPES & GRAY LLP
PRUDENTIAL TOWER
800 BOYLSTON STREET
BOSTON, MA 02199-3600
WWW.ROPESGRAY.COM
November 8, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention:
Mary Beth Breslin
Mary Mast
Irene Paik
Lisa Vanjoske
Re:
Agenus Inc.
Form 10-K for Fiscal Year Ended December 31, 2018
Response dated October 7, 2019
File No. 000-29089
Ladies and Gentlemen:
On behalf of Agenus Inc. (the “Company” or “Agenus”), we submit via EDGAR this letter in response to the written comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission, dated October 25, 2019 (the “Comment Letter”), with regard to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (filed March 18, 2019). For the convenience of the Staff’s review, we have set forth the comments contained in the Comment Letter in italics followed by the responses of the Company.
Form 10-K for Fiscal Year Ended December 31, 2018
Item 1. Business
Our Business, page 3
1. We note your response to our prior comment 2. However, terms such as “best-in-class” and “first-in-class” suggest that the product candidates are effective and likely to be approved. In future filings, please delete these references. If your use of these terms was intended to convey your belief that the products are based on a novel technology or approach and/or is further
Securities and Exchange Commission
Division of Corporation Finance
November 8, 2019
along in the development process than a third party, you may discuss how your technology differs from existing antibodies and, if applicable, that you are not aware of competing products that are further along in the development process. Statements such as these should be accompanied by cautionary language that the statements are not intended to give any indication that the product candidates have been proven effective or that they will receive regulatory approval.
Response:
The Company advises the Staff that it maintains that the applicable product candidates have the potential to be “best-in-class” and/or “first-in-class,” based on the preclinical and clinical data, and other information, provided to the Staff in response to comment 2 in the Company’s letter dated October 7, 2019. In future filings, the Company will revise its disclosure to include cautionary language that such statements are not intended to give any indication that the product candidates have been proven effective or that they will receive regulatory approval. The Company will also refer to these product candidates in a stage-appropriate way (i.e., preclinical or investigational) to clarify that such product candidates remain in preclinical or clinical trials and have not yet been approved.
Item 1A. Risk Factors
Risks Related to our Tokens, page 36
2. We note your responses to our prior comments 4-10 that you are not pursuing the offering of Tokens and will remove from future filings information regarding the Token offering. Please confirm that you will disclose in future filings, to the extent true, that you are not pursuing the offering of Tokens and have not issued any Tokens.
Response:
The Company acknowledges the Staff’s comment and confirms that in its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 7, 2019, the Company disclosed that it is not currently offering any Tokens at this time and that it has not issued any Tokens to date.
***
We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions or comments about this letter or need any further information, please call the undersigned at (617) 951-7663.
Very truly yours,
/s/ Zachary R. Blume
Show Raw Text
CORRESP 1 filename1.htm CORRESP ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM November 8, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Mary Beth Breslin Mary Mast Irene Paik Lisa Vanjoske Re: Agenus Inc. Form 10-K for Fiscal Year Ended December 31, 2018 Response dated October 7, 2019 File No. 000-29089 Ladies and Gentlemen: On behalf of Agenus Inc. (the “Company” or “Agenus”), we submit via EDGAR this letter in response to the written comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission, dated October 25, 2019 (the “Comment Letter”), with regard to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (filed March 18, 2019). For the convenience of the Staff’s review, we have set forth the comments contained in the Comment Letter in italics followed by the responses of the Company. Form 10-K for Fiscal Year Ended December 31, 2018 Item 1. Business Our Business, page 3 1. We note your response to our prior comment 2. However, terms such as “best-in-class” and “first-in-class” suggest that the product candidates are effective and likely to be approved. In future filings, please delete these references. If your use of these terms was intended to convey your belief that the products are based on a novel technology or approach and/or is further Securities and Exchange Commission Division of Corporation Finance November 8, 2019 along in the development process than a third party, you may discuss how your technology differs from existing antibodies and, if applicable, that you are not aware of competing products that are further along in the development process. Statements such as these should be accompanied by cautionary language that the statements are not intended to give any indication that the product candidates have been proven effective or that they will receive regulatory approval. Response: The Company advises the Staff that it maintains that the applicable product candidates have the potential to be “best-in-class” and/or “first-in-class,” based on the preclinical and clinical data, and other information, provided to the Staff in response to comment 2 in the Company’s letter dated October 7, 2019. In future filings, the Company will revise its disclosure to include cautionary language that such statements are not intended to give any indication that the product candidates have been proven effective or that they will receive regulatory approval. The Company will also refer to these product candidates in a stage-appropriate way (i.e., preclinical or investigational) to clarify that such product candidates remain in preclinical or clinical trials and have not yet been approved. Item 1A. Risk Factors Risks Related to our Tokens, page 36 2. We note your responses to our prior comments 4-10 that you are not pursuing the offering of Tokens and will remove from future filings information regarding the Token offering. Please confirm that you will disclose in future filings, to the extent true, that you are not pursuing the offering of Tokens and have not issued any Tokens. Response: The Company acknowledges the Staff’s comment and confirms that in its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 7, 2019, the Company disclosed that it is not currently offering any Tokens at this time and that it has not issued any Tokens to date. *** 2 We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions or comments about this letter or need any further information, please call the undersigned at (617) 951-7663. Very truly yours, /s/ Zachary R. Blume Zachary R. Blume cc: Evan Kearns (Agenus Inc.)